Related Experiment Video
Updated: Aug 19, 2026

Induction and Validation of Cellular Senescence in Primary Human Cells
Published on: June 20, 2018
The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence
Laura E Klein1, B Scott Freeze, Amos B Smith
1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA.
Abstract:
Discodermolide is a microtubule stabilizing agent that suppresses dynamic instability and blocks cells in mitosis. Selection of A549 nonsmall cell lung carcinoma cells with increasing concentrations of discodermolide yielded a clone that proliferated in 8 nM. When these cells were exposed to any concentration greater than 8 nM, replication ceased and the cells developed a flattened, enlarged, granular morphology. Accelerated senescence was demonstrated by a functional beta-galactosidase activity at pH 6. When parental A549 cells were treated with IC50-concentrations of doxorubicin, Taxol or discodermolide, the latter two drugs quickly produced aberrant mitosis. However, discodermolide, but not Taxol, also produced a large increase in senescence-associated beta-galactosidase activity and altered levels of known senescence markers. Although some of these differences between Taxol and discodermolide were dose dependent, only discodermolide produced a doxorubicin-like induction of a senescence phenotype, including a senescence-associated beta-galactosidase activity, up-regulation of PAI-1 and p66Shc, and a strong, sustained, Erk1/2 activation. This research provides insights into the mechanism of action of discodermolide and provides the first demonstration of a microtubule stabilizing agent that inhibits tumor cell growth with a powerful induction of accelerated senescence.
Insights
Discodermolide, a microtubule stabilizing agent, halts tumor cell growth by inducing accelerated senescence. This compound, unlike Taxol, triggers a doxorubicin-like senescence phenotype, offering new therapeutic insights.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Discodermolide is a microtubule stabilizing agent known to arrest cells in mitosis.
- Non-small cell lung carcinoma (NSCLC) cells can be selected for resistance to discodermolide.
- Understanding the full mechanism of action of discodermolide is crucial for its therapeutic development.
Purpose of the Study:
- To investigate the mechanism by which discodermolide inhibits tumor cell proliferation.
- To compare the cellular effects of discodermolide with other chemotherapeutic agents like doxorubicin and Taxol.
- To determine if discodermolide induces senescence in cancer cells.
Main Methods:
- Selection of A549 NSCLC cells for resistance to discodermolide.
- Treatment of parental A549 cells with discodermolide, doxorubicin, and Taxol at IC50 concentrations.
- Assessment of cell morphology, proliferation, beta-galactosidase activity, and senescence markers (PAI-1, p66Shc, Erk1/2 activation).
Main Results:
- A discodermolide-resistant clone of A549 cells was established.
- Discodermolide, but not Taxol, induced a doxorubicin-like senescence phenotype in parental A549 cells.
- This senescence induction involved increased beta-galactosidase activity, PAI-1 and p66Shc upregulation, and sustained Erk1/2 activation.
Conclusions:
- Discodermolide is a potent inducer of accelerated senescence in non-small cell lung carcinoma cells.
- This senescence-inducing property distinguishes discodermolide from Taxol and contributes to its tumor growth inhibition.
- Discodermolide represents a novel class of microtubule stabilizing agents with significant therapeutic potential due to its senescence-inducing mechanism.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Destabilization of Microtubules
Microtubule Instability
Replicative Cell Senescence
Negative Regulator Molecules
